CD38-directed Cytolytic Antibody
- CD38-directed Cytolytic Antibody
- Accession Number
Drug Drug Description Daratumumab A CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. Isatuximab A chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
- Drugs & Drug Targets
Drug Target Type Daratumumab ADP-ribosyl cyclase 1 target Isatuximab ADP-ribosyl cyclase 1 target